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Abstract
Objective: Adequate symptom control is a problem for many people with asthma. We asked whether weekly email reports
on monitored use of inhaled, short-acting bronchodilators might improve scores on composite asthma-control measures.
Methods: Through an investigational electronic medication sensor attached to each participant’s inhaler, we monitored
4 months’ use of inhaled, short-acting bronchodilators. Participants completed surveys, including the Asthma Control
TestTM (ACT), to assess asthma control at entry and monthly thereafter. After the first month, participants received weekly
email reports for 3 months. The reports summarized inhaled bronchodilator use during the preceding week and provided
suggestions derived from National Asthma Education and Prevention Program (NAEPP) guidelines. Paired t-tests and
random-effects mixed models were implemented to assess changes in primary asthma endpoints.
Results: Thirty individuals participated in the 4-month study; 29 provided complete asthma control information. Mean age
was 36.8 years (range: 19–74 years); 52% of respondents were female. Mean ACT scores were 17.6 (Standard Deviation [SD]
= 3.35) at entry and 18.4 (SD = 3.60) at completion of the first month. No significant difference appeared between ACT
values at entry and completion of the first month (p = 0.66); however, after participants began receiving email reports and
online information about their inhaler use, mean ACT scores increased 1.40 points (95% CI: 0.61, 2.18) for each subsequent
study month. Significant decreases occurred in 2-week histories of daytime symptoms (b= 21.35, 95% CI: 22.65, 20.04)
and nighttime symptoms (b= 20.84, 95% CI: 21.25, 20.44); no significant change in activity limitation (b= 20.21, 95% CI:
20.69, 0.26) was observed. Participants reported increased awareness and understanding of asthma patterns, level of
control, bronchodilator use (timing, location) and triggers, and improved preventive practices.
Conclusions: Weekly email reports and access to online charts summarizing remote monitoring of inhaled bronchodilator
frequency and location were associated with improved asthma control and a decline in day-to-day asthma symptoms.
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Introduction
Despite improved understanding and the development of new
medications, asthma remains a substantial and costly public health
problem [1]. Each year in the United States, 1.75 million asthma-
related emergency department visits and 456,000 asthma hospi-
talizations occur [2], with overall costs of $55 billion [1]. While
proper treatment could prevent the majority of exacerbations,
numerous studies suggest that a majority of people with asthma do
not have adequate control of their disease [3,4].
National Asthma Education and Prevention Program and
Global Initiative for Asthma clinical practice guidelines recom-
mend doctors monitor whether treatment is controlling symptoms
and improving quality of life [5,6]; however, physicians lack ways
to objectively assess how well patients manage asthma symptoms
between visits, and often underestimate the frequency and severity
of patients’ symptoms [7]. In addition, the majority of patients
with uncontrolled asthma report that their disease is well-managed
[3].
Questionnaires that capture composite asthma-control mea-
sures have become popular tools to help patients and their
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physicians determine level of control [7]. These questionnaires ask
patients to recall and report over some period of time symptom
frequency, activity level and restriction, and inhaler usage.
Underlying these instruments is evidence that symptom frequency
and bronchodilator use are important indicators of asthma
control, of current impairment, and of future risk of worsening
asthma [6,7].
This pilot study’s goals were 1) to investigate the use of a device
to monitor objectively the time and location of inhaled broncho-
dilator use as a measure of asthma control, and 2) to determine
whether information about inhaled bronchodilator use and
feedback on asthma control via weekly email reports was




The study was reviewed and approved by the University of
Wisconsin Health Sciences institutional review board (protocol H-
2007-0291) and all participants signed informed consent docu-
mentation.
Participants
We recruited adults (aged .18 years) from a variety of clinical
and community settings on a rolling basis between February and
April 2009. These adults had a diagnosis of asthma and used a
prescribed inhaled short-acting beta-agonist (SABA). By the end of
August 2009, all participants had participated for 4 months. At
entry, participants completed questionnaires to collect data on
their demographic and clinical characteristics, including asthma
history, then-current status, and asthma management such as
medical treatments, perceived triggers, healthcare utilization, and
level of control using the Asthma Control TestTM (ACT) [8].
We collected data about the time and location of use of inhaled
short-acting bronchodilators. This involved using a small and
portable investigational electronic medication sensor that is
attached to an existing inhaler housing by means of a hook-and-
loop fastener strap (Figure 1). This allows the sensor to be readily
transferred to a new inhaler when the medication is refilled. When
the sensor was attached to an inhaler, an actuation detection
assembly placed on the end of the medication canister monitored
the use of the inhaler and used a global positioning system (GPS)
receiver to determine the time and location of the inhaler
whenever it was used. Design verification and systematic bench
and human testing demonstrated that the sensor accurately and
reliably detected actuation of the inhaler and that expected
functioning was not sensitive to a precise method of attachment.
Participants were asked to keep the sensor attached to their
inhaled short acting bronchodilator for all 4 months of the study.
The device also contained equipment to communicate via a
wireless network and supporting electronics, including a simple
user interface, a power switch, and a rechargeable battery. The
device obtained and wirelessly communicated medication event
information in real-time to a remote server. It did not require that
the patient (or any other person) participate in obtaining or
transmitting the information. Because the routine dose of some
SABAs can vary from one to multiple inhalations, the device was
not designed to record each inhalation of medication but rather to
capture information about the occasion of medication use,
following American Thoracic Society/European Respiratory
Society guidance [7].
After completing the first month of the study, participants began
to receive weekly e-mail reports displaying maps and charts of
their usage. They also received access to an online interface with
similar features. This online interface allowed participants to
indicate when an inhaler was used prophylactically before
exercise. The weekly e-mail reports included the time and location
for each inhaled bronchodilator use and summarized use for the
preceding week. Participants received a basic assessment of their
asthma control based on the number of days of use in the
preceding week, the timing of those events, and on thresholds from
the National Asthma Education and Prevention Program
(NAEPP) guidelines. Participants also received simple advice
derived from the NAEPP guidelines about how to improve asthma
self-management (Appendix S1) [7].
At the conclusion of each month, and on conclusion of the study
in August 2009, participants completed questionnaires designed to
detect any changes in the four primary study outcome measures:
the Asthma Control TestTM score and 2-week histories of activity
limitation and days and nights with asthma symptoms. A score
#19 (of 25) on the Asthma Control TestTM was considered to
indicate uncontrolled asthma. We collected 2-week histories of
asthma symptoms and activity limitation to capture continuous
estimates of outcome measures in addition to the ordinal responses
gathered by the Asthma Control TestTM. Exit questionnaires also
assessed participant feedback that included the utility of the
electronic communications, perceived changes in asthma aware-
ness, and modifications in day-to-day asthma management.
Figure 1. GPS-enabled inhaler sensor as attached to inhaled
albuterol.
doi:10.1371/journal.pone.0055335.g001
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Statistical Tests
We used pairwise t-tests to evaluate the null hypothesis that
there was no change in the four primary study endpoints (Asthma
Control TestTM score; two-week histories of activity limitation and
days and nights with asthma symptoms) while participants were
blinded to data collected by the medication sensor in the first
month of participation. Linear mixed effects models with a
random effect for subject assessed changes in primary asthma
endpoints across the three subsequent months of enrollment (at the
completion of the first month, the second month, and the third
month, i.e., upon exit) when participants were able to access their
usage data online. Participants with one or more observations
were included in the analysis.
All analyses were performed with SAS 9.2 (SAS Institute, Cary,




A total of 33 individuals were initially recruited for the study
and 29 provided complete information on asthma control at entry.
Table 1 presents the demographic characteristics of the partici-
pants, who averaged 36.8 years of age (range: 19–74 years); 52%
of respondents were female. Four (14%) reported Hispanic
ethnicity. A broad range of socioeconomic backgrounds was
represented, including household income and educational achieve-
ment. Persons who completed the study did not differ significantly
from those who did not. In particular, there was no significant
difference in the proportion of males (95% CI: 219.8%, 36.4%),
in age (p = 0.80), or in years of diagnosis (p = 0.95) in the group
that enrolled compared to the group that completed the study.
On average, participants had longstanding asthma, with a mean
time since diagnosis of 25 years (standard deviation [SD] = 16).
Approximately 62% (18/29) of study participants entered with
uncontrolled asthma; mean ACT score at study entry for
uncontrolled participants was 15.4 (SD = 2.11). Mean ACT score
overall was 17.6 (SD = 3.35).
At study entry, participants reported 4.84 days (SD = 4.13) with
asthma symptoms, 2.03 (SD = 3.35) nights with asthma symptoms,
and 0.86 (SD = 1.38) days with activity limitations in the 2 weeks
before entry (Table 2). More than half (62%; 18/29) of
participants reported current use of anti-inflammatory therapy
(e.g., an inhaled corticosteroid). There was no significant relation
between report of an inhaled corticosteroid and ACT score at
study entry (Fisher’s exact test: p = 1.00). Approximately one-third
of the participants reported receiving $1 course of oral steroids in
the past year, and nearly 40% reported an unscheduled doctor
visit in the past year (Table 1).
Observed inhaler use
Participants were enrolled for a total of 3,887 patient-days of
observation between March and August 2009. Of these days,
devices were turned on and available on 1,916 days –49% of
patient-days. On the other days, devices were powered off or out
of range of a wireless network.
On average, participants used the devices on 27% (520/1,916)
of patient-days in which the devices were active, and 13% (520/
3,887) of patient-days overall. During the study period, the devices
reported a total of 958 medication-use events, occurring on 520
patient-days. The median number of events per day was 1.35, with
a mode of 1. The percentage of days on which individual
participants used bronchodilators ranged from 1% to 83%.
Overall, participants who entered the study with controlled
asthma (11/29) as defined by the Asthma Control TestTM (score
.19) used bronchodilators on 25% of the days their devices were
active, compared with 37% among those with uncontrolled
asthma.
Effect of intervention
A total of 30 individuals provided information for at least one of
the periodic (monthly) surveys. Results from the pairwise t-test
(Table 3) indicate that from study entry to the end of the first
month, while participants were blinded to their data on inhaler
usage, no significant differences appeared in the ACT score
Table 1. Demographic and clinical characteristics of




Mean Age, in years(range){ 36.8 (19–74)












Smoker in house 7%
Education
Completed college and above 59%
Health care utilization
Oral steroids in past year 31%
ED visit for asthma ever 59%
Hospitalization for asthma ever 24%
Unscheduled doctor visit past year 38%
Urgent care visit past year 24%
Current treatment
Controller medication** 59%
Main source of asthma care
Family practice 59%
Internal medicine 7%
Specialist (allergy, pulmonology) 34%
Preventive asthma care
Action plan 14%
Influenza vaccination last year 59%
Peak flow meter 52%
Asthma symptom diary -
*Presented as percent unless otherwise indicated; {Value missing for one
participant; #Information missing for three participants; -Zero value; **
Controller medication limited to any inhaled anti-inflammatory therapy.
doi:10.1371/journal.pone.0055335.t001
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(p = 0.66). In addition, no significant differences appeared in the 2-
week history of daytime symptoms, nighttime symptoms, or
activity limitations from the entry period to the first-month survey.
After the first month that participants received weekly email
reports, mean ACT scores increased 1.5 points to 20.1 (SD = 3.66).
After a second month of reports (at exit), mean ACT scores
increased an additional 1.1 point to 21.2 (SD = 3.36)(Table 2). At
exit, 70% of participants had improved ACT scores, 15% had no
change, and 15% had worsened. Scores for the worsened patients
(n = 3) declined an average of 0.9 points. Overall, at the conclusion
of the study period, 75% of participants had controlled asthma (by
ACT score) compared with 38% at entry.
Table 4 shows results from the repeated-measures analysis.
Each month of participation following the availability of inhaler
usage data through the online interface and weekly email reports
resulted in a 1.40 point (95% CI: 0.61, 2.18) increase in the
Asthma Control TestTM score. Receipt of weekly e-mail reports
and online access to asthma event history was also associated with
a significant decrease in number of days with symptoms
(b= 21.35, 95% CI: 22.65, 20.04) and number of nights with
symptoms (b= 20.84, 95% CI: 21.25, 20.44). We did not
observe a significant change in the frequency of activity limitation
reported by participants. Regression diagnostics indicated that
linearity assumptions were adequately met for the primary
analyses.
On exit surveys, participants reported that the weekly email
reports increased their awareness of the frequency and patterns of
asthma symptoms. Participants suggested that the feedback helped
improve perceptions of their asthma control and their ability to
communicate to their physicians their level of control. As one
participant described, ‘‘I learned that I used my inhaler more than
I remember. I was able to see and relate to my doctor that my
asthma is not under control.’’ Participants also reported that the
receipt of information about the time and location where they used
their inhaler helped to highlight locations and exposures to triggers
that led to symptoms. ‘‘I’ve been more keen to note surroundings
when I feel shortness of breath,’’ one participant said. ‘‘It opened
my eyes to triggers I wasn’t aware of in the past.’’ Some described
subsequent attempts to minimize or avoid exposure. Finally,
participants reported that weekly feedback helped to reinforce
their use of controller medications. ‘‘I’m now using my controller
medicine more regularly and on time,’’ one participant told us. ‘‘I
noticed that my rescue inhaler use went down significantly when
using a daily inhaler as well.’’
Participants reported that remote monitoring and feedback
proved a practical aid. All but one of the participants indicated
that the weekly e-mail reports were either very or somewhat useful
in improving their asthma management; overall, 80% expressed
an interest in continuing to track their inhaler use.
Discussion
The findings from this pilot study suggest that capturing data
on inhaled bronchodilator use, incorporating that information
with some basic asthma education, and putting it all into a
simple, weekly e-mail report may be associated with improved
asthma control. The majority of participants in this study
experienced small, but statistically significant and steady increases
in composite measures of asthma control and significant declines
in the day-to-day burden of asthma symptoms. We observed a
mean per month increase of 1.4 points in ACT score, or 2.8
points overall, slightly less than the Minimal Important
Difference of 3 points [10]; however, no plateau in improvement
was observed during the study period. The availability of real-
time information on the frequency and time of day of
Table 2. Reported days with symptoms, nights with
symptoms, and activity limitation in preceding two weeks,
and Asthma Control TestTM(ACT) score.
n Mean SD*
Days with Sx{ (days)
Entry 29 4.84 4.13
First Month# 21 4.95 4.43
Second Month** 18 2.77 3.56
Exit 20 2.92 2.16
Nights with Sx (nights)
Entry 29 2.03 3.35
First Month 21 1.85 2.10
Second Month 18 0.55 0.98
Exit 20 0.15 0.49
Activity Limitations (days)
Entry 29 0.86 1.38
First Month 21 1.14 1.62
Second Month 18 0.50 1.04
Exit 20 0.95 2.28
Asthma Control TestTM (score out of 25)
Entry 29 17.6 3.35
First Month 23 18.4 3.60
Second Month 18 20.1 3.66
Exit 21 21.2 3.36
*SD = standard deviation; {Sx = symptoms; #First Month denotes the first month
that participants received weekly email reports; **Second Month denotes the
second month that participants received weekly email reports.
doi:10.1371/journal.pone.0055335.t002
Table 3. Paired t-tests for difference in asthma outcomes between study entry and first month.
Outcome n Entry Mean
First Month
Mean Mean Difference SD# t{ p value
Days with Sx* 20 4.35 5.20 0.85 3.99 20.95 0.35
Nights with Sx* 20 1.20 1.95 0.75 1.83 21.83 0.08
Activity Limitations 20 0.75 1.20 0.45 1.76 21.14 0.26
ACT score 22 18.18 18.41 20.23 2.37 20.45 0.66
*Sx = symptoms;#SD = standard deviation;{t = t-statistic.
doi:10.1371/journal.pone.0055335.t003
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bronchodilator use allowed rapid, automated assessment of
asthma control.
This study provided patients with novel feedback about the
ongoing management of their asthma. Today, many patients have
inappropriately low expectations for their own disease control or
are unaware that more can be done to prevent attacks and day-to-
day symptoms. In one recent study, more than 4 in 5 individuals
with poorly controlled asthma regarded their disease as well
controlled or very well controlled [3]. Others fail to voice concerns
or to report troublesome symptoms. This study has demonstrated
that simple interventions that use objectively collected data from
daily life may provide patients with valuable information to help
guide management and achieve control of their disease. These
interventions can help individuals with asthma assess their level of
asthma control and can provide ways to convey that information
to their doctors.
A number of recent studies have demonstrated that internet- and
mobile phone-based self-management interventions can improve
asthma control and asthma-related quality of life [11–15]. As many
proven asthma self-management tools such as asthma action plans
and asthma symptom diaries are still not widely used [16], new
methods of delivering personalized, targeted self-management
materials online and via mobile phone have the potential to
increase adoption and engagement, potentially benefiting many
patients. This study suggests that technology and rapid feedback in
the form of charts, graphs, and maps can make self-management
more interesting and compelling, and can play a valuable role in
developing and reinforcing better habits, particularly when
integrated with a comprehensive education and self-management
program. Such a system can be extended to remotely monitor the
inhaler use of patients in real time. Also, it can routinely evaluate
medication use against physician-established thresholds or national
guidelines. Patients in need of additional review or attention could
be automatically identified, and providers or family members could
be contacted as necessary.
The results of this pilot study are subject to numerous
limitations. In particular, this study purposefully enrolled a small
convenience sample of adult volunteers with relatively uncon-
trolled asthma that does not represent that general population
with asthma or specific asthma phenotypes. Participants in the
study did not undergo reversibility studies to confirm their
reported diagnosis of asthma, nor were pulmonary function
studies performed to quantify the severity of airflow limitation.
Given the age range of participants, it remains possible that some
persons may have also had undiagnosed chronic obstructive
pulmonary disease. In addition, not all participants in this study
provided complete information on all questionnaire outcomes at
all time points. While attrition may have introduced some bias,
persons who did not provide complete information or who
withdrew did not differ significantly from those who completed
the study. That many individuals continued to contribute
information from the electronic medication sensor even when
they failed to respond to asthma control questionnaires
underscores the unique potential role and value of passively
collected data in the remote monitoring of asthma control.
This study was also limited by its relatively short duration and
the lack of a control group to isolate the effect of time-varying
covariates (such as environmental exposures) known to influence
asthma. As a result, it is not possible to know if participants would
have improved regardless of the intervention (due, for example, to
regression to the mean or seasonal trends). Subsequent research
with a randomly selected sample and a randomized and controlled
protocol of greater duration is underway to isolate and assess the
effect and persistence of remote monitoring and feedback on
management. Stratification by level of control at entry should also
strengthen the analysis and interpretation [13]. Finally, despite the
positive reception from the community and the enthusiasm of
participants, we found that two individuals failed to keep the
device adequately charged for much of the study. This resulted in
periods where no inhaler use (or absence of use) could be recorded.
Fortunately, the wireless nature of the device allows us to create an
accurate record of the days during which the device was operating,
and this minimized potential bias.
This pilot study has identified a number of areas where additional
research could improve the value of remote monitoring and patient
feedback, and underscores the need for evaluation of its potential
effects in a properly designed and conducted randomized-controlled
trial. For example, more information is required to understand how
participants interpret weekly feedback and how often they share
reports with friends, family, and health care providers. Further
research is also needed to determine whether providing patients
with information about their patterns of inhaler use motivates them
to adhere better to preventive therapy, or increases the probability
that patients undertake environmental interventions or behavior
changes to reduce exposures that cause attacks. Finally, we
recommend additional research to identify which composite
measure of asthma control, or combination of questions from
available instruments, best captures current impairment and future
risk when used in conjunction with information about rescue and
controller medication use captured by remote monitoring devices.
Remote monitoring of inhaled bronchodilator use may also be
valuable for epidemiological research and public health surveil-
lance. By aggregating individual patterns of inhaler use, epidemi-
ologists and public health groups can use the accumulated data to
strengthen their ongoing asthma surveillance activities, improve
scientific understanding of disease triggers and progression in the
community, and provide a novel source of data about the local
burden of disease through which to examine the response to
treatment and interventions. Data can also target and evaluate
interventions designed to reduce asthma-related morbidity in the
community. Monitoring the timing and location of use of inhaled
bronchodilators provides instant, objective data on the burden and
frequency of asthma symptoms in populations. With widespread use
it may also reveal clusters of asthma exacerbations and help identify
new epidemiological patterns and risk factors, particularly when
used as part of focused investigations.
Conclusion
Receipt of weekly email reports with asthma management
guidance and access to online materials summarizing use of
Table 4. Results for repeated measures analysis of asthma
outcomes per month during the intervention period (from








Days with Sx* 21.35 0.62 22.65 20.04
Nights with Sx* 20.84 0.19 21.25 20.44
Activity
Limitations
20.21 0.22 20.69 0.26
ACT score 1.40 0.37 0.61 2.18
*Sx = symptoms;#SE = standard error;{CI = confidence interval.
doi:10.1371/journal.pone.0055335.t004
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inhaled bronchodilators was associated with improved measures
of asthma control. Such a system has the potential to improve
the recognition and treatment of poorly controlled asthma. It
could also represent an important improvement in asthma
management, epidemiological research, and public health
surveillance.
Supporting Information
Appendix S1 Sample weekly email report.
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